Zydus Pharmaceuticals
-
{
- All
- News
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
Gujarat Pharma Firm Recalls Over 55,000 Medicine Bottles From US Market
The affected lot is manufactured by Ahmedabad-based Zydus Lifesciences and marketed in the US by New Jersey-based Zydus Pharmaceuticals (USA) Inc.
-
Zydus Cadila's US Firm Gets US Approval To Market Roflumilast Tablets
Cadlia Healthcare Ltd on Monday said group firm Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market its generic version of Roflumilast tablets in the strength of 500 mcg indicated to reduce the risk of
-
Zydus Cadila Begins Supply Of Covid Vaccine ZyCoV-D To Government
Pharmaceutical company Zydus on Wednesday announced that it has started the supplies of its COVID-19 vaccine ZyCoV-D to the Government of India against their order from its newly commissioned state-of-the-art.
-
Drug Regulator Examining Zydus Cadila's Covid Vaccine For Children: Dr VK Paul
Drugs Controller General of India (DCGI) is examining pharmaceutical major Zydus Cadila's COVID-19 vaccine for children, said Dr VK Paul, Member-Health, Niti Aayog on Friday.
-
Zydus Cadila Shot For 12-18 Soon, Centre Informs Supreme Court
A new coronavirus vaccine developed by Indian pharmaceutical company Zydus Cadila will be available soon for those between 12-18 years of age, the central government said in an affidavit to the Supreme Court on Saturday.
-
Zydus Cadila May Seek Emergency Use Approval For Vaccine Next Week: Report
Indian pharmaceutical major Zydus Cadila is likely to apply to the central drugs regulator seeking emergency use authorisation for its COVID-19 vaccine ZyCoV-D next week, official sources said on Friday.
-
Human Trials Of Second COVID-19 Vaccine Candidate Begin
Indian pharmaceutical giant Zydus Cadila has initiated the phase 1, 2 clinical trial to evaluate the safety and immunogenicity of coronavirus vaccine candidate by intradermal (injection) route in 1,048 subjects after the pharma company got approval from Drugs Controller General of India (DCGI) earlier this month.
-
Second COVID-19 Vaccine Cleared For Phase I, II Human Trials In India
The Drug Controller General of India has approved pharmaceutical firm Zydus Cadila to start Phase I and Phase II human clinical trials of its COVID-19 vaccine. This is the second vaccine after Hyderabad-based Bharat Biotech's COVAXIN to get the approval.
-
Zydus Cadila Gets USFDA Nod To Drug That Treats Severe Acne Vulgaris
Zydus Pharmaceuticals has received the final approval from the USFDA to market Minocycline Hydrochloride Extended Release Tablets
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
Gujarat Pharma Firm Recalls Over 55,000 Medicine Bottles From US Market
The affected lot is manufactured by Ahmedabad-based Zydus Lifesciences and marketed in the US by New Jersey-based Zydus Pharmaceuticals (USA) Inc.
-
Zydus Cadila's US Firm Gets US Approval To Market Roflumilast Tablets
Cadlia Healthcare Ltd on Monday said group firm Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market its generic version of Roflumilast tablets in the strength of 500 mcg indicated to reduce the risk of
-
Zydus Cadila Begins Supply Of Covid Vaccine ZyCoV-D To Government
Pharmaceutical company Zydus on Wednesday announced that it has started the supplies of its COVID-19 vaccine ZyCoV-D to the Government of India against their order from its newly commissioned state-of-the-art.
-
Drug Regulator Examining Zydus Cadila's Covid Vaccine For Children: Dr VK Paul
Drugs Controller General of India (DCGI) is examining pharmaceutical major Zydus Cadila's COVID-19 vaccine for children, said Dr VK Paul, Member-Health, Niti Aayog on Friday.
-
Zydus Cadila Shot For 12-18 Soon, Centre Informs Supreme Court
A new coronavirus vaccine developed by Indian pharmaceutical company Zydus Cadila will be available soon for those between 12-18 years of age, the central government said in an affidavit to the Supreme Court on Saturday.
-
Zydus Cadila May Seek Emergency Use Approval For Vaccine Next Week: Report
Indian pharmaceutical major Zydus Cadila is likely to apply to the central drugs regulator seeking emergency use authorisation for its COVID-19 vaccine ZyCoV-D next week, official sources said on Friday.
-
Human Trials Of Second COVID-19 Vaccine Candidate Begin
Indian pharmaceutical giant Zydus Cadila has initiated the phase 1, 2 clinical trial to evaluate the safety and immunogenicity of coronavirus vaccine candidate by intradermal (injection) route in 1,048 subjects after the pharma company got approval from Drugs Controller General of India (DCGI) earlier this month.
-
Second COVID-19 Vaccine Cleared For Phase I, II Human Trials In India
The Drug Controller General of India has approved pharmaceutical firm Zydus Cadila to start Phase I and Phase II human clinical trials of its COVID-19 vaccine. This is the second vaccine after Hyderabad-based Bharat Biotech's COVAXIN to get the approval.
-
Zydus Cadila Gets USFDA Nod To Drug That Treats Severe Acne Vulgaris
Zydus Pharmaceuticals has received the final approval from the USFDA to market Minocycline Hydrochloride Extended Release Tablets
